Latest Conference Articles

Digital health can improve care around the world, but if used poorly could exacerbate existing disparities, said Ejim E. Mark, MD, MPH, MBA, CEO and founder of Access Healthcare Foundation.

In order to start evaluating the economics of new cures, the scope of the evaluation needs to be as broad as possible and be able to wrestle with uncertainty, said Steven Pearson, MD, MSc, founder and president of the Institute for Clinical and Economic Review.

Advances in medicine have produced breakthroughs in the treatment of a number of rare diseases, but these advances often come at a high cost. A multi-stakeholder panel at the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, in Baltimore, Maryland, addressed the question of how to define value in the always evolving and ever more expensive treatment landscape.

As new therapies come to market, there is the good news that patients are cured or living longer, but it has to be balanced by the bad news that these treatments are far more expensive, said Paul Billings, senior vice president advocacy for the American Lung Association.

Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.

In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.

Researchers based at the University of Michigan compared patients admitted to the intensive care unit (ICU) in Medicaid expansion states with those in nonexpansion states, focusing on 18 specific conditions identified as severe illnesses that could be avoided through better preventive care.

From smartphones to smart rescue inhalers, researchers offered ideas to make chronic obstructive pulmonary disease care more data-driven and personalized.

How valuable are digital data collection tools in healthcare and what do they mean to the patient? Are they helpful or is this revolution merely a hype? These were some of the discussions during the plenary session on the second day of the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting.

Legislation, advancing science, and more sophisticated patient advocacy has led to a proliferation of new therapies to treat rare diseases, and society has begun to indicate a willingness to pay for these more expensive therapies, said Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.

Navigating FDA's rules to get a fixed-dose combination therapy for chronic obstructive pulmonary disease approved required a large study and a specific population.

Two scientists taking part in a session on addiction and pulmonary health outlined existing evidence about marijuana's effects on chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and cancer. But one speaker warned there are too few longitudinal studies in this area.

Using technology and collected data can greatly improve care coordination, but some low-tech options, like better team communication and involving the patient are also important, explained Barbara Tofani, RN, MSN, NEA-BC, administrative director of the Hunterdon Regional Cancer Center.

There is a monumental amount of data being collected in healthcare, but now it’s time to make sure that data is empowered so it can start being used to answer questions and improve decision making, said Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe.

At the first plenary session at the ISPOR 2018 conference, May 19-23 in Baltimore, Maryland, panelists updated the audience on how digital progress can influence real-world evidence to allow near real-time data analysis and inclusion of specific patient information, lowering cost and providing higher quality care downstream.

In a Monday panel convened at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, stakeholders grappled with the role that value assessments play—or should play—in US private payer coverage and formulary decisions.

The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).

Results presented at the American Thoracic Society 2018 International Conference confirm a hypothesis about the connections among pollution, inflammation, and oxidative stress.

Innovations are transforming healthcare, but these innovations have to align with business models and they still have to be validated before they can improve care delivery, explained Harlan Krumholz, MD, SM, Harold H. Hines Jr professor of Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.

A session at the American Thoracic Society 2018 International Conference examined the factors that contribute to disparities and potential partnerships between doctors and lawyers on behalf of patients.

Looking at how burnout affects specialties differently shows that it’s not a work–life balance issues, but a systems one, said Kathleen Blake, MD, MPH, vice president for Performance Improvement at the American Medical Association.

Officials with GlaxoSmithKline said COLUMBA is the first long-term study for an anti-IL5 biologic to treat severe asthma that has been reported.

Attendees at the American Thoracic Society 2018 International Conference, meeting in San Diego, California, heard details that led to FDA's recent expansion of the indication for GlaxoSmithKline's Trelegy Ellipta, including findings that the once-daily combination also provides significant mortality benefits over a dual therapy that is often the combination patients with chronic obstructive pulmonary disease (COPD) are taking when triple therapy is recommended.

Calvin Knowlton, BScPharm, MDiv, PhD, chief executive officer and founder of Tabula Rasa HealthCare, discusses innovative practices that have been introduced in Enhanced Medication Therapy Management (eMTM) and what he sees in the future for eMTM improvement and innovation.

Beyond helping with co-payment assistance for patients with cancer, CancerCare helps with practical and emotional supports for patients, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

Tina Joseph, PharmD, BCACP, assistant professor, college of pharmacy, Nova Southeastern University, discusses the role of pharmacists in helping manage chronic diseases and the transition for integrating pharmacists into value-based care models.

Lee Newcomer, MD, MHA, private consultant, discusses the differences between UnitedHealthcare's pilot episodic payment model and CMS models.

Gathering data to use it to improve care delivery is easier said than done, explained Charles Saunders, MD, CEO of Integra Connect.